https://www.selleckchem.com/pr....oducts/gsk2126458.ht
Different treatment costs pertaining to the population were applied according to the usage data (IQVIA Singapore National Sales Data) for different scenarios. Drug costs were obtained from public-sector hospitals. Exacerbation management costs were obtained from literature searches. The analysis showed that increased access to FP/FORM as a result of switching from FP/SAL could help achieve drug (S$1,042,289) and exacerbation management (S$223,55 cost savings over 5 years. In the scenario where patients switched from BUD/FORM, great
Like
Comment
Share
